Oculis Holding has concluded subject enrolment for the Phase III DIAMOND-1 and DIAMOND-2 clinical trials of OCS-01 eye drops ...

Argentine football legend Diego Maradona’s daughter told a court yesterday his death “would have been avoided” if doctors ...

Swollen feet may signal more than fatigue Read ahead to find out how they’re linked to heart failure and other conditions ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

Alimera Sciences announced a change to the Summary of Product Characteristics (SmPC) for its intravitreal implant, Iluvien ...

Although there is wide variation in the cause, location, and characteristics of chronic wounds, collectively, chronic wounds ...

Biocon Biologics Ltd (BBL), the biosimilars company and subsidiary of Biocon Ltd, has announced a licence agreement with Regeneron to commercialise Yesafili, a drug used to treat ophthalmological ...

This agreement enables the company to launch in the US in the second half of calendar year 2026 or earlier in certain circumstances ...

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.

You will be able to get a quick price and instant permission to reuse the content in many different ways. Recent referrals to our intensive care unit have led us to question the indication for ...